FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128482308> ?p ?o ?g. }

• W2128482308 abstract "Henoch-Schönlein purpura (HSP) is the most common vasculitis of childhood but may occur in adults. This small vessel vasculitis is characterised by palpable purpura, abdominal pain, arthritis or arthralgia and kidney involvement. This is an update of a review first published in 2009.To evaluate the benefits and harms of different agents (used singularly or in combination) compared with placebo, no treatment or any other agent for: (1) the prevention of severe kidney disease in patients with HSP without kidney disease at presentation; (2) the prevention of severe kidney disease in patients with HSP and minor kidney disease (microscopic haematuria, mild proteinuria) at presentation; (3) the treatment of established severe kidney disease (macroscopic haematuria, proteinuria, nephritic syndrome, nephrotic syndrome with or without acute kidney failure) in HSP; and (4) the prevention of recurrent episodes of HSP-associated kidney disease.We searched the Cochrane Kidney and Transplant's Specialised Register to 13 July 2015 through contact with the Trials Search Co-ordinator using search terms relevant to this review.Randomised controlled trials (RCTs) comparing interventions used to prevent or treat kidney disease in HSP compared with placebo, no treatment or other agents were included.Two authors independently determined study eligibility, assessed risk of bias and extracted data from each study. Statistical analyses were performed using the random effects model and the results were expressed as risk ratio (RR) or risk difference (RD) for dichotomous outcomes and mean difference (MD) for continuous outcomes with 95% confidence intervals (CI).Thirteen studies (1403 enrolled patients) were identified. Risks of bias attributes were frequently poorly performed. Low risk of bias was reported in six studies (50%) for sequence generation (selection bias) and in seven (58%) for allocation concealment (selection bias). Blinding of participants and personnel (performance bias) and of outcome assessment (detection bias) was at low risk of bias in three studies. Five studies reported complete outcome data (attrition bias) while eight studies reported expected outcomes so were at low risk of reporting bias.Eight studies evaluated therapy to prevent persistent kidney disease in HSP. There was no significant difference in the risk of persistent kidney disease any time after treatment (5 studies, 746 children: RR 0.74, 95% CI 0.42 to 1.32), or at one, three, six and 12 months in children given prednisone for 14 to 28 days at presentation of HSP compared with placebo or supportive treatment. There were no significant differences in the risk of persistent kidney disease with antiplatelet therapy in children with or without kidney disease at entry. Heparin significantly reduced the risk of persistent kidney disease by three months compared with placebo (1 study, 228 children: RR 0.27, 95% CI 0.14 to 0.55); no significant bleeding occurred. Four studies examined the treatment of severe HSP-associated kidney disease. Two studies (one involving 56 children and the other involving 54 adults) compared cyclophosphamide with placebo or supportive treatment and found no significant benefit of cyclophosphamide. There were no significant differences in adverse effects. In one study comparing cyclosporin with methylprednisolone (15 children) there was no significant difference in remission at final follow-up at a mean of 6.3 years (RR 1.37, 95% CI 0.74 to 2.54). In one study (17 children) comparing mycophenolate mofetil with azathioprine, there was no significant difference in the remission of proteinuria at one year (RR 1.32, 95% CI 0.86 to 2.03). No studies were identified which evaluated the efficacy of therapy on kidney disease in participants with recurrent episodes of HSP.There are no substantial changes in conclusions from this update compared with the initial review. From generally low quality evidence, we found no evidence of benefit from RCTs for the use of prednisone or antiplatelet agents to prevent persistent kidney disease in children with HSP. Though heparin appeared effective, this potentially dangerous therapy is not justified to prevent serious kidney disease when fewer than 2% of children with HSP develop severe kidney disease. No evidence of benefit has been found for cyclophosphamide treatment in children or adults with HSP and severe kidney disease. Because of small patient numbers and events leading to imprecision in results, it remains unclear whether cyclosporin and mycophenolate mofetil have any roles in the treatment of children with HSP and severe kidney disease." @default.
• W2128482308 created "2016-06-24" @default.
• W2128482308 creator A5030548857 @default.
• W2128482308 creator A5038938109 @default.
• W2128482308 creator A5051609819 @default.
• W2128482308 creator A5056074771 @default.
• W2128482308 date "2015-08-07" @default.
• W2128482308 modified "2023-10-06" @default.
• W2128482308 title "Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP)" @default.
• W2128482308 cites W1523184546 @default.
• W2128482308 cites W1575082163 @default.
• W2128482308 cites W1970530828 @default.
• W2128482308 cites W1971491273 @default.
• W2128482308 cites W1978910083 @default.
• W2128482308 cites W1981514045 @default.
• W2128482308 cites W1986079204 @default.
• W2128482308 cites W1987454050 @default.
• W2128482308 cites W1987880803 @default.
• W2128482308 cites W1990494489 @default.
• W2128482308 cites W1994462432 @default.
• W2128482308 cites W1999284622 @default.
• W2128482308 cites W2002694041 @default.
• W2128482308 cites W2011017816 @default.
• W2128482308 cites W2011932878 @default.
• W2128482308 cites W2017823628 @default.
• W2128482308 cites W2028155613 @default.
• W2128482308 cites W2030192997 @default.
• W2128482308 cites W2031517139 @default.
• W2128482308 cites W2032921505 @default.
• W2128482308 cites W2047471909 @default.
• W2128482308 cites W2054213145 @default.
• W2128482308 cites W2062041134 @default.
• W2128482308 cites W2065224672 @default.
• W2128482308 cites W2065279564 @default.
• W2128482308 cites W2073250741 @default.
• W2128482308 cites W2077609687 @default.
• W2128482308 cites W2081196250 @default.
• W2128482308 cites W2087438494 @default.
• W2128482308 cites W2087947010 @default.
• W2128482308 cites W2100180749 @default.
• W2128482308 cites W2101767970 @default.
• W2128482308 cites W2102647537 @default.
• W2128482308 cites W2107325626 @default.
• W2128482308 cites W2115992160 @default.
• W2128482308 cites W2121310692 @default.
• W2128482308 cites W2125435699 @default.
• W2128482308 cites W2128482308 @default.
• W2128482308 cites W2129887999 @default.
• W2128482308 cites W2147141737 @default.
• W2128482308 cites W2149377529 @default.
• W2128482308 cites W2154387748 @default.
• W2128482308 cites W2158785079 @default.
• W2128482308 cites W2160764274 @default.
• W2128482308 cites W2160795579 @default.
• W2128482308 cites W2361189703 @default.
• W2128482308 cites W2362226482 @default.
• W2128482308 cites W2364510693 @default.
• W2128482308 cites W2396732199 @default.
• W2128482308 cites W2405944196 @default.
• W2128482308 cites W2409762563 @default.
• W2128482308 cites W2410637776 @default.
• W2128482308 cites W2411402231 @default.
• W2128482308 cites W2460981940 @default.
• W2128482308 cites W2467728037 @default.
• W2128482308 cites W3149837303 @default.
• W2128482308 cites W4214559180 @default.
• W2128482308 cites W4234760746 @default.
• W2128482308 cites W4236171894 @default.
• W2128482308 doi "https://doi.org/10.1002/14651858.cd005128.pub3" @default.
• W2128482308 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26258874" @default.
• W2128482308 hasPublicationYear "2015" @default.
• W2128482308 type Work @default.
• W2128482308 sameAs 2128482308 @default.
• W2128482308 citedByCount "67" @default.
• W2128482308 countsByYear W21284823082012 @default.
• W2128482308 countsByYear W21284823082013 @default.
• W2128482308 countsByYear W21284823082014 @default.
• W2128482308 countsByYear W21284823082015 @default.
• W2128482308 countsByYear W21284823082016 @default.
• W2128482308 countsByYear W21284823082017 @default.
• W2128482308 countsByYear W21284823082018 @default.
• W2128482308 countsByYear W21284823082019 @default.
• W2128482308 countsByYear W21284823082020 @default.
• W2128482308 countsByYear W21284823082021 @default.
• W2128482308 countsByYear W21284823082022 @default.
• W2128482308 countsByYear W21284823082023 @default.
• W2128482308 crossrefType "journal-article" @default.
• W2128482308 hasAuthorship W2128482308A5030548857 @default.
• W2128482308 hasAuthorship W2128482308A5038938109 @default.
• W2128482308 hasAuthorship W2128482308A5051609819 @default.
• W2128482308 hasAuthorship W2128482308A5056074771 @default.
• W2128482308 hasBestOaLocation W21284823082 @default.
• W2128482308 hasConcept C126322002 @default.
• W2128482308 hasConcept C141071460 @default.
• W2128482308 hasConcept C142724271 @default.
• W2128482308 hasConcept C168563851 @default.
• W2128482308 hasConcept C204787440 @default.
• W2128482308 hasConcept C27081682 @default.
• W2128482308 hasConcept C2776015282 @default.
• W2128482308 hasConcept C2778653478 @default.

• next